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Introduction
Thyrotrophs are basophilic TSH hormone-pro-
ducing cells occurring in pars distalis (pd) and pars
tuberalis (pt) of the adenohypophysis. These cells are
involved in the regulation of thyroid hormones se-
cretion through the hypothalamic-pituitary-thyroid
complex. Within the thyrotrope subsets other neuro-
endocrine peptides are co-localized with TSH hormo-
ne- secretogranins/chromogranins, a highly conserved
polypeptide termed 7B2, a neuropeptide substance P,
neuromedin B, galanin, and calretinin. Based on pre-
viously reported data, they may function as local mod-
ulators of TSH secretion in an autocrine or a paracrine
fashion. However, the precise function of these neu-
roendocrine peptides in thyrotrophs is yet to be ex-
plained.
Hypothalamic neurons secrete multiple regula-
tors of TSH secretion. Among these regulators TRH as
a stimulator and somatostatin and dopamine as
inhibitors are considered to be of utmost importance.
TRH acts to stimulate at first the release and later on
the synthesis of TSH, while thyroid hormones (T3 and
T4) inhibit these functions in a classic way of negative
feedback control. Somatostatin antagonizes the bio-
logical effects of TRH in thyrotrophs. This is the main
basis of the integrated neuroendocrine control system
of the TSH secretion. 
The synthesis and secretion of adenohypophy-
seal hormone TSH is strongly influenced by steroid
hormones, as well. The effects of estrogen hormones
are mediated through the genome and these steroids
strongly influence homeostatic functions and develop-
ment of the adenohypophysis. Besides the estrogens,
the androgens are also involved in determining the cel-
lular composition of the anterior pituitary, but whether
the effect of these steroids are direct or mediated via
the hypothalamus remains to be elucidated.
Calcium plays a pivotal role in stimulus-secretion
coupling in endocrine cells. In addition, a rise in cyto-
solic free calcium concentration represents a key step
in signal transduction of a wide range of secretago-
gues in adenohypophyseal secretory cells.
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Summary: The pituitary gland is a heterogenous tissue comprised of several hormone-secreting cells most
of which are targeted by sex steroids. Our long-term studies were concentrated on the response  of rat pituitary
TSH cells to gonadal steroids applied to animals of different age. With this goal, we examined immunoreactive
and morphometric, as well as subcellular organization of pituitary TSH cells in rats of both sexes after neonatal
and perinatal estradiol-dipropionate (EDP) treatment. The results undoubtedly indicated persistent EDP-related
inhibitory changes of tyrotrophs up to the adulthood. At the subcellular level, a delayed differentiation of TSH cells
was noticed. Besides, a special attention has been paid to the changes in the structure of immunoreactive TSH
cells of middle-aged (14-month-old) rat females, chronically treated with EDP, calcium (Ca) or a combination of
EDP and Ca. Based on our results it can be concluded that both EDP and Ca act inhibiting the thyrotrophs under
the applied experimental conditions.
Key words: rat pituitary, thyrotrophs, estradiol, calcium, immunohistochemistry,  ultrastructure
Although sex steroids and calcium are widely
applied in human medicine, there are sparce data in
the available literature concerning their influence on
pituitary TSH cell structure and function. Keeping in
mind previous experience in this area, the present
study was focused on the changes in pituitary TSH
cells after a single or chronic treatment of rats of dif-
ferent age with estradiol and calcium, or the combina-
tion of both. For this purpose, cytological, histoche-
mical, stereological and biochemical methods have
been employed. 
Pituitary TSH cells 
According to Li (1) basophilic cells producing
glycoprotein hormones such as TSH, FSH and LH,
synthesize the hormones originating from the same
ancestor molecule. Yoshimura et al. (2) described six
types of basophilic cells in rat pituitary. This division
included the intermediary cell forms between the
above three types of cells. Applying immunoelectron
microscopy Hirano et al. (3) demonstrated that b-sub-
units of FSH, LH and TSH are colocalized in the same
anterior pituitary cells of mush shrews. These authors
termed these cells thyrogonadotrophs and suggested
them to be a potential stem or progenitor from which
thyrotrophs and gonadotrophs have diversed in more
advanced mammals. Horvat et al. (4) described in hy-
pothyroid rats bihormonal thyrosomatotrophs con-
taining GH and TSH in dilated rough endoplasmic
reticulum and their secretory granules. These results
sugest that one cell-one hormone theory in the ade-
nohypophysis is untenable.
In rat fetuses the first immunoreactive TSH cells
were noticed on day 17. of gestation (5), while in
murine fetuses they were detected on day 16. of ges-
tation, and no sex-related differences were observed
(6). Cluster formation of neogenic thyrotrophs begins
on day 3, and the size and incidence of the clusters
reach a maximum on a day 10. Thereafter, the clus-
ters break down to give rise to singly scattered neo-
genic thyrotrophs, as reported by Yoshiro et al. (7).
These authors (7) suggested that fetal thyrotrophs are
not precursors of neogenic TSH cells, but rather may
differentiate from pituitary primordial or folliculo-stel-
late cells. After the birth, during the period of weaning,
at 5’7 days of age, the percentage of thyrotrophs is
relatively high. The percentage of thyrotrophs estab-
lished on day 15. of postnatal life represents 4’ 6% of
the pituitary cell population in adult rats (8). The pro-
liferation of thyrotrophs affects the lifespan of the rat
through the activity of the thyroid gland (9). In old rats,
a decrease of thyroid weight accompanied by a loss of
cellular elements and reduction of pituitary TSH cell
activity was reported (10). In contrast, no involution of
thyrotroph cells in human pituitary gland in aged indi-
viduals was observed (11).
Differentiation of TSH cells in the pt starts earlier
than that in the pd, from the day 14. of gestation.
Numerous authors demonstrated that the secretory
activity of TSH pt-specific cells varies with age. It was
found to be the highest perinatally, declining in young
rats and increasing again in adult animals (12’15, 18).
This early differentiation together with a high secreto-
ry activity during the fetal and early postnatal period
suggests that the pt TSH cells play a key role in devel-
opmental processes. It has been shown that both TSH
subunits (TSHa and b) of rat and hamster are expre-
ssed in pt-specific cells. Morphologically TSH pt cells
are smaller than the thyrotrophs of the pd and do not
resemble them (16). The function of the pt TSH cells
is still uncertain. Hypophyseal pars tuberalis TSH cells
are not regulated via the classic thyrotroph receptors
and their intracellular pathways, but through a novel,
photoperiod-dependent mechanism (16). It appears
likely that the pt cells are a pacemaker for the differ-
entiation and secretory activity of pd thyrotrophic or
gonadotrophic cells (17, 18). In contrast to secretory
cells of the pd, the specific pt cells do not respond to
functional changes of peripheral endocrine glands by
morphological alterations. Also, it is worth mentioning
that melatonin receptors were detected on the pt TSH
cells of fetal and newborn rats (19, 20). Thus, these
cells may relate between the epiphysis cerebri and the
thyroid or the gonads. The pt-specific cells synthesize
a novel glycoprotein hormone, tentatively termed
tuberalin, with a distinct b-subunit that varies from one
to another species (17,18).
The classic morphological aspect and ultrastruc-
tural immunocytochemical observations defined the
pituitary pd TSH cells as polygonally shaped with a few
small secretory granules (100’150 nm in diameter)
along the cell periphery. These are the smallest secre-
tory granules whithin various cell types in the anterior
pituitary. A normal thyrothroph contains spherical gra-
nules and little cytoplasm, while cell organelles such as
the rough endoplasmic reticulum, Golgi apparatus
and mitochondria are poorly developed (21’ 25). Ap-
plying immunogold electron microscopy, Ozawa and
Kurosami (26) identified three subtypes of TSH cells
during postnatal development of rats: immature
(between the birth and 10 days of postnatal life), inter-
mediate (between 10 and 30 days of age) and mature
ones (over 30 days of age). Immature TSH cells are
oval with a few small secretory granules (50 ’100 nm
in diameter) and poorly developed cell organelles. The
intermediate subtype TSH cells are polygonal or stel-
late containing a moderate number of medium sized
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secretory granules (80’120 nm in diameter) and mod-
erately or well developed cell organelles. Mature sub-
type TSH cells are large, polygonal in shape and con-
tain numerous large secretory granules (120’180 nm
in diameter) and well developed cell organelles.
Besides the TSH, many regulatory peptides are pres-
ent in specific secretory granules. The secretogra-
nins/chromogranins (Sgs/Cys) were shown to be colo-
calized with thyrotropin and luteinizing hormone in
secretory granules of the bovine anterior pituitary (27).
A highly conserved polypeptide termed 7B2 has also
been reported within the secretory vesicles of the
LH/FSH and TSH pituitary cells of rat (28). The sub-
stance-P-immunoreactive cells were found to colocal-
ize with a small subpopulation of TSHb-immunoreac-
tive cells in human and rat pituitary and these results
suggest a relationship between the substance-P and
thyroid gland function (29, 30). Other neuroendocrine
peptides, e.g. neuropeptide-Y, neuromedin-B and ga-
lanin have also been identified within the rat thyrotroph
subsets (31’ 33). Thyrotrophs, gonadotrophs and lac-
totrophs of the rat pituitary were immunocytochemi-
cally stained with rabbit anti-TRH sera (34). Calretinin
was identified as a calcium-binding protein in the rat
thyrotrophs. It may be involved in the release and/or
synthesis of TSH in thyrotrophs through the regulation
of intracellular calcium level (35). Thyrotrophs also
synthesize transcription factor Pit-1, which is shown to
be necessary for thyrotroph development and survival
(36). Lin et al. (37) proposed two separate populations
of thyrotrophic cells designated Pit-1-independent and
Pit-1-dependent thyrotrophs. The former are reported
to be a transient population existing only in the fetal
pituitary, whereas latter population exists in both the
fetal and the adult pituitary. Several authors have
reported that the development of thyrotrophic, soma-
totrophic and lactotrophic cells is dependent on the
presence of the Pit-1 transcription factor (35, 38, 39).
Thyroid-stimulating hormone (TSH)
Thyroid-stimulating hormone (TSH) is a member
of pituitary glycoprotein hormone family, besides LH
and FSH. Each molecule of the hormone consists of
two noncovalently bound subunits, a and b. The a-
subunit is common to all three above mentioned hor-
mones, while the b-subunit is unique for each of them
and confers biological specificity of the heterodimer
(40 ’42). TSH-like molecules are found widely distri-
buted throughout the rodent central nervous system.
They possess immunologic, chromatographic and bio-
logic activity similar to that of the pituitary TSH (43).
Molecular mass of TSH is 28 kD. It is aproxima-
tly 200 times larger than T4, a thyroid product, the
secretion of which is controlled by TSH. It should be
pointed out that at different physiological states quali-
tatively different forms of TSH are secreted (44). 
TSH is synthesized at ribosomes attached to the
rough endoplasmic reticulum (RER). The newly syn-
thesized proteins are transported across the RER
lumen to the cis-most Golgi stack and from it to the
next one trans side what is mediated by transporting
vesicles. While passing through the Golgi apparatus,
secretory proteins get post-translationally processed
and glycosylated. Microtubules and granule-associat-
ed filaments are also involved in the transport of the
secretory granules. The modified secretory proteins
are concentrated and packed in secretory granules
and transported to the cell periphery. The content of
secretory granules, i.e. secretory proteins, are released
to the cell exterior by the means of exocytosis (45). 
Subcellular fractionation studies disclosed that
the combination of a- and b-subunits begins in the
RER at early developmental stages and that these
combining subunits are endoglycosidase H-sensitive.
All glycoprotein hormones have a relatively high car-
bohydrate content and the a- and b-subunits of TSH
contain approximately 21% and 12% carbohydrates
respectively (46). In the Golgi apparatus, high man-
nose oligosaccharides are converted to complex oligo-
saccharides which modulate biological activity of gly-
coprotein hormones and contain fucose, N-acetylgala-
ctosamine sulfate and sialic acid residues (44).
Both the synthesis and production of all pituitary
hormones are shown to be efficiently regulated at the
transcriptional level. TSH a- and b-subunits are
encoded by distinct genes on different chromosomes
and are synthesized as separate peptides from distinct
mRNA (11, 42, 44, 47). The a-subunit gene is expres-
sed in the thyrotrophs and gonadotrophs of the ante-
rior pituitary and trophoblast cells of the placenta. In
rats, it consists of 4 exons (48) and is 13.5 kb long.
The expression of the TSH b-subunit is restricted to
the thyrotrophs (49). Rat TSH b-gene consists of 3
exons and is 4.9 kb long (50, 51). Since the a-gene is
expressed in gonadotrophs, as well as in thyrotrophs,
it may be anticipated that it contains multiple regula-
tory elements as various hormonal and physiological
effectors (42). Based on the results obtained with cell
cultures of newborn rat testicles and ovaries, Chaba et
al. (52) suggested cross-effect between gonadotrop-
hins (FSH, LH) and thyrotrophin (TSH). TSH b-gene
expression seems to be under a tight control of cell-
specific transcription factors such as the pituitary fac-
tor Pit-1 (53). 
It should be mentioned also that the pituitary-
derived TSH of different species was reported to have
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substantially different biopotencies. So, human TSH
was found to be 29- and 10-fold less potent than
bovine and rat TSH, respectively (44).
Regulation of thyrotrophin 
synthesis and secretion
Hypothalamic regulation of TSH
It is generally accepted that hypothalamic regu-
latory peptides called »releasing hormones« regulate
their specific target cells in pd of the adenohypophysis.
Secretion of the TSH is regulated by hypothalamic
hormones, TRH as a stimulator and somatostatin and
dopamine as inhibitors, as well as by circulated thyroid
hormones.
TRH is a tripeptide (pyroglutamyl-histidyl-prolin-
eamide) separated and identified by research groups
of Schally (54) and Guillemin (55). It is synthesized
within hypothalamic »peptidergic neurons« of the thy-
rotrophic area, that extends from the paraventricular
and supraoptic nuclei to the anterior border of the
median eminence (56). Merduenthaler et al. (57) sho-
wed that TRH-immunoreactive neurons exist not only
in the hypothalamus but also througout the central
and peripheral nervous system, in endocrine cells and
in the anterior pituitary itself. In long-term monolayer
cultures, TRH may act as a paracrine or autocrine reg-
ulator (58). All these findings suggest that TRH is not
only a hypophysiotrophic hormone but an important
neurotransmitter and/or a modulator, as well. In par-
vocellular paraventricular nucleus (PVN) neurons, that
are directly influenced by the central epinephrinergic
system, it may act as a neuromodulator upon other
paraventricular neurons.
At the ultrastructural level the TRH-synthesizing
neurons express general morphological features of
peptidergic hypophysiotrophic hormone-producing
cells of the diencephalon, as reported by Liposits et al.
(59). Small subcellular particles containing TRH are
present in the hypothalamus of 22-day-old fetuses,
whereas large particles containing TRH are visible by
the seventh day of neonatal life (60). On the postnatal
day 4, the portal vein of rats penetrates the external
layers of the median eminence to transport the releas-
ing hormones from the hypothalamus to the anterior
pituitary (61). On the other hand, Jackson (38) noticed
that the pituitary-thyroid axis is relatively independent
of the hypothalamus in neonatal rats, and only after
day 10. of life the hypothalamus becomes critical for
the regulation of TSH secretion. Before the portal sys-
tem is established, TRH cannot act directly on the
pituitary thyrotrophs, even though they may be sensi-
tive to TRH during the fetal period (62). It has been
reported that TRH can cross the placenta of the rat
(63) and monkey (64). So, the i.v. administration of
TRH to the maternal monkey caused a stronger
response in the fetal plasma TSH than in that of the
mother. 
After one day of the PVN destruction in thy-
roidectomized rats, a significant decrease in median
eminence TRH content with a concomitant decrease
of blood TSH level occurred (65, 66). TRH receptors
in the anterior pituitary are profoundly regulated by
thyroid hormones, but not significantly by TRH itself
(65). Donda et al. (67) observed that the density of the
TRH receptors was higher in the aged than in the
young rats, but no changes in the affinity constant
were recorded. A primary physiological action of TRH
in the thyrotroph is to control the set-point for thyroid
hormone negative feedback on TSH secretion. How-
ever, this does not appear to be the sole mechanism
by which TRH influences TSH secretion since even 2
months after thyroidectomy, when plasma-TSH con-
centration had plateaued, TSH level was lower by 50%
in PVN comparing to that in sham-operated rats (68).
Hyperthyroidism reduces the hypothalamic re-
lease of TRH into the hypophyseal portal system, sug-
gesting that a part of the feedback action of thyroid
hormones is exerted at the level of the hypothalamus
(69). The central noradrenergic system plays an im-
portant role in the regulation of TSH secretion under
various physiological conditions (70).
Besides, leptin, a peptide hormone produced by
the adipose tissue, was found to lead to an increased
TRH expression, as well as to a simultaneous activa-
tion of the autonomic nervous system. Little is known
so far about a potential feedback regulation between
the TRH-producing nerves and the sympathetic and
parasympathetic centers in the hypothalamus (71).
The action of TRH on the hypophyseal TSH
secretion is very rapid and can be detected already
within one minute after the TRH injection (72). Bre-
nner-Gati et al. (73) suggested that TSH release could
be probably due to more than one mechanism. The
acute effects of TRH were interpreted to be caused by
the opening of Ca2+ cellular channels and of extracel-
lular Ca2+ influx into the TSH cells. On the other hand,
a more chronic effect may be a consequence of the
activation of phospholipase C by TRH, leading to a
cascade of phosphatidylinozitol hydrolysis, inositol
1,4,5-triphosphate (IP3) formation and its interaction
with the endoplasmic reticulum stores of calcium,
thus leading to a rise in the intracellular Ca2+ concen-
tration (74). TRH also activates adenylate cyclase in
the pituitary thyrotrophs and mammotrophs, but this
is not an important mechanism for the induction of
either TSH or prolactin release (75, 76). 
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In addition to stimulating TSH release, TRH sti-
mulates TSH synthesis in rat pituitary, as well. Ultra-
structural and morphometric studies on the rat pitu-
itary revealed that TRH accelerates synchronously
both the secretion and the synthesis of TSH (77). This
effect is performed primarily by the stimulation of the
transcription of both TSH a- and b-mRNA (42), as well
as during posttranslational carbohydrate processing
(78, 79). 
It is also worth mentioning that several authors
(80 ’83) suggested that somatostatin (SRIH) and do-
pamine, acting at the pituitary level as neurohormones
and neurotransmitters, can contribute to the CNS
modulation of the TSH release.
The inhibitory action of somatostatin (SRIH) was
confirmed by discrete lesions of SRIH neurons in the
rat periventricular nucleus of the preoptic-anterior
hypothalamus, leading to a transient elevation in GH
and TSH secretion (84). Roussel et al. (85) showed
that SRIH inhibits TSH response to physiological con-
centrations of TRH in primary cultures of rat anterior
pituitary cells in a dose-dependent manner. Similarly,
increased hypothalamic SRIH levels induced by oral
glucose administration, were found to suppress TRH-
stimulated TSH response in humans (86).
Centrally administered somatostatins (SRIH-14
and SRIH-28) were reported to inhibit TSH cells in rats
of both sexes. During our recent studies, the morpho-
metric analyses revealed a decreased volumetric den-
sity of TSH-immunoreactive cells in SRIH-treated ani-
mals, but this difference was more expressed in SRIH-
14-treated animals than in those receiving SRIH-28
(87, 88). 
James et al. (89) demonstrated a synergistic
action of thyroid hormone thyroxin (T4) and somato-
statin in the control of TSH secretion, expressing both
anti-secretory and anti-proliferative effects on pituitary
thyrotroph tumours in mice. Somatostatin also decre-
ased pituitary TSH secretion, caused tumour shrink-
age when used for the treatment of human pituitary
thyrotropinomas and suppressed proliferation of a hu-
man differentiated thyroid carcinoma cell line (90, 91). 
Biological actions of SRIH-14 are receptor-medi-
ated and specific receptors were found not only in the
CNS, but also in the pituitary (92). In the adenohypo-
physis, SRIH-binding sites were identified on the three
target cell types: somatotrophs, thyrotrophs and lac-
totrophs (93, 94). Coy and Rossowski (95) suggested
the presence of several subtypes of somatostatin re-
ceptors and successfully cloned five of them.
Since dopamine receptors have been demon-
strated in the rat anterior pituitary, it is likely that this
neurotransmitter directly exerts its inhibitory influence
on the thyrotrophs (96). Dopamine administration has
been associated with a decreased mRNA production
and a decreased TSH secretion in rat pituitary cells as
reported by Shupnik et al. (42). Overall, dopamine was
shown to cause a conspicuous decrease in the TSH
mRNA levels that reached even 50% comparing to the
corresponding control (97). Stimulation of hypothala-
mic dopamine by thyroid hormones was reported to
inhibit TSH and PRL secretion. It was suggested that it
could act either within the hypothalamus by inhibiting
TRH peptidergic neurones or directly at the pituitary
level by inhibiting the thyrotrophs (98).
Peptide hormones control TSH cells and
autoregulatory mechanisms of action
The anatomy of the pd permits hormonal pa-
racrine and electrotonic communication. The hormo-
nes released into the extracellular space of the adeno-
hypophysis from any epithelial cell reach the capillaries
by diffusion and enter them through the fenestrations
in their endothelial tubes (99). Also, hormones
released by one epithelial cell are free to interact with
neighbouring cells that contain appropriate receptors
situated in their cell plasma membranes (100).
Numerous neural peptides have been reported to
affect TSH secretion. According to Schwartz and
Cherny (101), these neural peptides include neu-
rotensin, angiotensin II and endothelin 3. In addition,
neuromedin 3, a bombesin-related peptide found in
the thyrotrophs, as well as in the hypothalamus, was
demonstrated to act inhibiting the TSH secretion
through the action at both the hypothalamic and the
pituitary level where it may have an autocrine regula-
tory function (102). Neurotensin (NT) as a neuroactive
tridecapeptide secreted from gonadotrophs and thy-
rotrophs may act in an autocrine or a paracrine fashi-
on and thereby modulate the secretion of other ante-
rior pituitary hormones. When administered intrave-
nously, NT stimulates the TSH secretion, but intrace-
rebroventricular NT injections were found to act in-
hibiting the TSH secretion as reported recently by
Bello et al. (103). Also, Jackson (38) observed an inhi-
bition of the pituitary-thyroid axis by opioid peptides
and the alkaloid morphine.
Rondel et al (69) identified TRH-like peptides in
the rat pituitary gland, but their biological significance
is still uncertain. The novel TRH-related peptide pGlu-
Glu-ProNH2 was isolated by Aschworth (104) from the
reproductive tract and pituitary gland of rats, pigs and
rabbits in significant concentrations. However, it is not
yet clear whether this TRH-related peptide exerts its
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effects via the TRH receptor or a second receptor is
involved.
Arginine vasopressin (AVP) as a neuropeptide
was found to stimulate the secretion of both TSH and
ACTH. Namely, based on the increased percentages
of TSH, ACTH and ACTH-TSH cells observed after the
stimulation by AVP, Childs et al. (105) suggested a
direct effect of this neuropeptide on these cell popula-
tions. The results of Frawley et al. (106) demonstrated
that oxytocin representing another polypeptide hor-
mone attenuated TRH-induced TSH release by a di-
rect action on pituitary cells. Galanin, a 29 amino acid
peptide, located in PVN may play an inhibitory role in
the regulation of TSH secretion, presumably by affect-
ing TRH secretion (107). It should be mentioned also
that Toni et al. (108) observed that neuropeptide Y
(NPY), a 36 amino acid peptide, occurs in neurons
innervating TRH-synthesizing neurons in the rat hypo-
thalamic PVN.
The 1.25-dihydroxy-vitamin D3 was shown by
Tornquist and Lamberg-Allard (109) to express a stim-
ulative effect on the TRH-induced TSH release in rats,
but the exact mechanism of its action remained ob-
scure. These authors suggested that 1,25-(OH)2-D3
could affect calcium influx or some other calcium-
transporting event in the pituitary and affect the TSH
release by this route.
Arisawa et al. (110) hypothesized that the sub-
stance-P, another polypeptide, could regulate the TSH
release in estrogen-primed rats. 
Regulation of TSH by thyroid hormones
TSH secretion increases only when plasma thy-
roxin (T4) decreases and that occurs when the hor-
mone store in the thyroid is sufficiently depleted (111).
Several authors demonstrated that the concentration
of thyroid hormones is the most important physiolog-
ical inhibitor of TSH synthesis and release (42, 112).
The inhibitory effects are not merely the results of a
direct antagonism of the TRH effects. They can be
observed when the hypothalamic source of TRH is
destroyed or the pituitary separated from it in vitro or
in vivo. Pekary et al. (113) reported a 66% decrease in
basal TRH release by hypothalami of aged rats in vitro,
as well as reduced serum T4 levels, while the serum T3
and TSH were maintained within the normal range of
concentrations. These data suggests that a gradual
loss of the essential TRH stimulation of TSH release
with ageing may be compensated by a decline in T4
inhibition of TSH release at the pituitary level. Low cir-
culating levels of thyroid hormones T4 and T3 in aged
rats may also contribute to an increased density of
TRH receptors, since T3 is known to exert an inhibito-
ry control on pituitary TRH receptors (114).
The ability of thyroid hormones to inhibit TSH
secretion is mediated through its effects on the thy-
rotrophs, TRH neurons and also via the regulation of
somatostatin secretion. The results of Peterfreund et
al. (115) revealed that thyroid hormones act stimulat-
ing hypothalamic somatostatin secretion, while the
hypothalamic content of somatostatin is reduced in
hypothyroidal rats.
3,5,3'-Triiodothyronine (T3) derived either by
intrapituitary conversion by the type II 5'-deiodinase or
directly from the circulating T4, binds to a specific
nuclear receptors as demonstrated by Murakami et al.
(116). There are two subtypes of nuclear thyroid hor-
mone receptors (TR): TRa and TRb (117). The TRb2
isoform occurs in both the anterior pituitary and the
hypothalamus (118), thus providing a mechanism
through which T3 regulates the TSH and TRH secre-
tion. Attachment of T3 to TRb2 activates the T3-recep-
tor complex that binds to the specific nucleotide
sequences referred to as thyroid response elements in
the promoter region of the genes for TSH a- and b-
subunit (42, 119). This thyroid hormone profoundly
decreases transcription of the TSHa and TSHb genes,
but the degree of suppression is greater for the latter
than for the former gene.
Calcium-dependent TSH secretion 
Besides the above listed hormones, secretory
processes in the anterior pituitary are controlled by
regulatory molecules such as inorganic ions, calcium,
vitamins, metabolites and growth factors (120). Nu-
merous cell functions, e.g. secretion, contraction,
excitation, proliferation and differentiation depend on
intra- and extracellular Ca2+ concentration. In general,
cytoplasmic calcium appears to be the principal regu-
lator of secretion in neuroendocrine cells, with cAMP-
dependent or protein kinase C-mediated pathways
serving to modulate Ca-dependent steps (121).
According to Fisher and Polk (122) and Zorec
(123), the release of TSH from the thyrotrophs is a Ca-
dependent process. Exocytosis is regulated by extrin-
sic, as well as intrinsic inputs to the pituitary, by hypo-
thalamic hormones reaching the pituitary via the por-
tal system and by local paracrine or autocrine factors
(124).
TRH modulates the action potentials of isolated
pituitary cells by increasing the free cytosol Ca2+ level.
This mechanism is mediated either through the stim-
ulation of calcium influx, or by its mobilization from
intracellular stores, or both (125). As the main function
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of the modulation of action potential in pituitary cells
is linked to signalling via voltage-gated Ca2+ channels,
their predominant role was presumed by Mollard and
Schlegel (126). According to Peters et al. (58) calcium
ionophore A 23187 may be involved in Ca influx. 
Gillet at al. (127) and Bergenfelz et al. (128) re-
ported decreased TSH levels in individuals after differ-
ent types of Ca2+ treatment. Our recent results clearly
showed that chronic treatment of middle-aged rat
females whith calcium evoked degranulation in glyco-
protein-produced pituitary cells (gonadotrophs and
thyrotrophs) and decreased the volume and the num-
ber of these cells, what could be interpreted as a sign
of their reduced synthetic capacity (129, 130). Be-
sides, our new data indicates a significant decrease of
serum TSH after this treatment of middle-aged rat
females (to be published).
Steroid hormones are involved 
in the control of TSH 
Sex steroids regulate the TSH activity
Several adenohypophyseal hormone-producing
cell types including lactotrophs (131, 132), gonado-
trophs (133), somatotrophs and thyrotrophs (134) are
known targets for estrogens. Estrogen-induced chan-
ges are presumably mediated via specific intracellular
estrogen receptors, ERa and ERb (135). According to
Mitchner et al. (136) only 10% of pituitary cells coex-
press both ERa and ERb. These authors suggested
that ER heterogeneity contributes to the diversity of
pituitary cell responsivness to estrogens.
Miller et al. (137) reported that estradiol 17-b
produced a five-fold increase in TSH secretion and a
two-fold increase in intracellular TSH concentration in
cell cultures and might stimulate TSH secretion by
causing proliferation of TSH-producing cells. Estro-
gens not only affect the synthesis and secretion of di-
fferent pituitary hormones, but also influence the sen-
sitivity of adenohypophyseal target cells to the hypo-
thalamic neuropeptide TRH (138). In the presence of
elevated estrogen concentrations, an increase of TRH
receptor level was observed both in vitro and in vivo
and this may account for the heightened sensitivity of
pituitary cells to TRH (139, 140). Donda et al. (141)
also reported that these hormones acted increasing
the density of both T3 and TRH receptors in the rat
anterior pituitary gland. 
In normal adult rats, proliferative activity of the
anterior pituitary is linked to the circadian changes,
oestrus cycle and sex (142). In female rats, the num-
ber of TSH-positive cells expressing NT-immunoreac-
tivity, as well as the intensity of histochemical reaction,
oscillate during the oestrus cycle. So, they are high
during dioestrus and decreased through pro-oestrus,
as observed by Bello et al. (103). These authors also
suggested that sex steroids may control both the NT
synthesis and release by direct actions on thyrotrophs. 
Estrogen is widely applied in human medicine for
the prevention and treatment of different sympthoms
and diseases. Rather than a linear response mediated
solely through estrogen-responsive DNA elements, in
vivo estrogens might simultaneously activate distinct
signalling cascades that function as networks to coor-
dinate tissue response to these hormones. Quite re-
cently, Segars and Driggers (143) claimed that this
complex signalling system provides an exquisite con-
trol and plasticity of response to estrogens at tissue
level and undoubtedly contributes to a remarkable tis-
sue-specific responses to these sex steroids. Because
of the occurrence of both beneficial and undesirable
effects during estrogen treatment, it is of great impor-
tance to completely understand their effects on all
organs, even those that are not specific therapy tar-
gets, among them the hypothalamo-pituitary-thyroid
axis. Zaninovich et al. (144) consider that pharmaco-
logical doses of estrogens can acutely depress thy-
roidal iodine release in healthy individuals and suggest
that such an estrogen action is associated with an ele-
vated serum TSH levels. D'Angelo (145) reported that
increased doses of estradiol given to female rats pro-
duce a progressive decline in TSH concentration both
in the pituitary and in the blood plasma and as a result
the TSH level was reduced by 40’90%. The same
author suggested that suppression of TSH secretion in
females who received large doses of estradiol probably
originate from a disturbance in the feedback relation-
ship between the thyroid gland and the hypophysis.
However, Boado et al. (146) demonstrated that estra-
diol injection produces a significant decrease in pitu-
itary TSH content, without affecting its release into the
circulation. Chronic treatment of animals with estro-
gens results in suppression of expression of all tree
gonadotrophin subunit genes LHb, FSHb and a-gly-
coprotein subunit (42). Rutlin et al. (147), however,
claimed that estrogens do not affect pituitary TSH
secretion. The results of Kulig et al. (148) demonstrat-
ing that the treatment of hypothyroid a-subunit knock-
out mice with 17b-estradiol had no influence on thy-
rotroph hyperplasia contribute to this hypothesis. 
Ovariectomy was shown to affect the function of
thyrotrophs, as well. The level of TRH-like peptide
pyroglutamyl-glutamyl-prolineamide localized in the
rat anterior pituitary gland was significantly increased
after gonadectomy in rats of both sexes, while the
treatment of gonadectomized rats with testosterone or
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estradiol 17-b returned the level of this peptide within
the range of normal values. It was concluded that the
level of TRH-like peptide in the anterior pituitary gland
seems to be regulated by peripheral sex steroids (149).
In contrast to this, bilateral ovariectomy (Ovx) induced
a dramatic reduction in the number of NT-immunore-
active cells. This effect was completely prevented by
the treatment of Ovx rats with estradiol and proges-
terone (103). Our data suggests that chronic treat-
ment of Ovx rats with pharmacological doses of EDP
influences both the morphological and stereological
features of TSH cells, as well as the serum level of TSH
in an inhibitory manner. 
In castrated rats TRH occurs in high concentra-
tions in the ventral prostate and it is regulated in a pos-
itive dose-dependent manner by testosterone (150).
When rat males received estradiol, the enzymatic acti-
vity of TRH-degrading ectoenzyme decreased to 65%
of control values. This means that the expression of
the adenohypophyseal TRH-degrading ectoenzyme
was down-regulated by estradiol (138).
The characteristics of the TSH cells response to
gonadal steroids depends on the dose, as well as on
the sensitivity of the cells to a hormone at different
stages of differentiation. We have shown previously
that neonatal treatment of the rats with EDP results in
a reduced number and decreased volume densities of
TSH immunoreactive cells (151). At the subcellular
level and under experimental conditions applied thro-
ughout our studies, a delayed differentiation of TSH
cells was noticed. The reduction of dense core vesicles
in TSH cells positively correlates with the pronounced
reduction of TSH-like immunoreactivity, i.e. the chan-
ges in the intensity of the TSH-like immunoreactivity of
EDP-treated rats could be explained by a diminution of
the secretory granules density (152, 153). The results
of our earlier studies demonstrated that neonatal treat-
ment of the rats with EDP also inhibited the ability of
gonadotrophic cells to synthesize, store and release
gonadotrophins (154’156).
Perinatal treatment of rat females with EDP led
to a decreased activity of TSH cells up to the peripu-
bertal period of life and these changes were expressed
to a lesser degree than in gonadotrophic pituitary cells
(157). In addition, under the same experimental con-
ditions an increase of »gap junction« communication
between the pituitary folliculo-stellate cells was noticed
(158).
The results of our previous studies also demon-
strated that chronic treatment of middle-aged rat fe-
males with EDP inhibits gonadotrophin secretion and
affects morphometric and immuno-histochemical
characteristics of FSH, LH and TSH cells (159, 160).
In addition, we have observed that EDP acted inhibit-
ing the thyroid follicular cells, thus decreasing the level
of thyroid hormones (161, 162). 
Glucocorticoids regulate TSH activity
Several authors showed that dexamethasone
(DEX), a synthetic glucocorticoid hormone, signifi-
cantly depressed both TRH- and cold-induced TSH
secretion in humans and rats (163’165). Brown and
Hedge (166) reported that the effect of DEX on TSH
secretion depends on various factors such as the do-
se, steroid-stimulus interval and stimulus-observation
interval. Some studies demonstrated that glucocorti-
coid hormones may act directly on the hypothalamus
regulating TRH release or could primarily affect TSH
secretion at the pituitary level (165, 167, 168).
Wilbur and Utiger (167) have claimed that gluco-
corticoids reduce the TSH secretion by acting at the
same suprahypophyseal level and Brown and Hedge
(169) showed that DEX can exert potentiating or
inhibitory effects on this system at both pituitary and
suprapituitary sites. 
It is possible that the effect of DEX on pituitary
sensitivity is mediated via the changes in T4 levels
(169). However, these authors (170) provided no evi-
dence on increased pituitary responsiveness to TRH
due to DEX pretreatment. Contrary to this, Faglia et al.
(171) showed that in healthy humans DEX might act
directly at the pituitary level by reducing the resposnse
of TSH to TRH, while not altering significantly the
serum T4 and T3 uptake.
TRH-induced TSH release was shown to be
inhibited in patients who were receiving glucocorticoid
hormones either for prolonged periods of time, or in
high doses and this TSH response to TRH was clearly
dose-dependent (163). Also, it has been demonstrated
that glucocorticoids have a suppressing effect on the
TSH response to TRH in young and elderly men (172).
Glucocorticoids decrease hypothalamic prepro-
TRH mRNA synthesis both directly and indirectly via
somatostatin. However, in vitro studies have shown
upregulation of the prepro-TRH transcript by DEX in
several cell lines. This discrepancy may be explained
by the in vivo complexity of prepro-TRH gene regula-
tion vs. the deafferentiated in vitro system (173). En-
hanced hypothalamic somatostatinergic and dopami-
nergic inhibitory activities are involved in the mecha-
nism underlying a reduced TSH response to TRH in-
duced by glucorticoid treatment in healthy humans as
recently reported by Coiro et al. (174).
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Glucocorticoids suppress TSH secretion and the
activity of 5'-deiodinase. Thus, during stress, secretion
of TRH and TSH is suppressed, while the conversion
of T4 into the biologically active T3 is decreased in the
pituitary. These could be the reasons why the patients
suffering from melancholic depression, anorexia, then
highly trained athletes, as well as the patients with
chronic, inflammatory diseases have a significantly lo-
wer thyroid hormone concentration than age-matched
healthy controls (173).
Conclusions
The sensitivity and character of response of pitu-
itary TSH cells to gonadal steroids and calcium has
been studied in rats of different age and both sexes.
Based on the data presented in this review, the follow-
ing general conclusions may be drawn out:
The administration of a single high dose of EDP
during the critical neonatal period of development pro-
duces a long-term effect on the anterior pituitary cells.
Neonatally applied EDP to male and female rats acts
affecting pituitary immunoreactive TSH cells in an
inhibitory manner, as judged by the changes at the
level of structure and ultrastructure up to the maturity.
At the same time, hyperplasia of chromophobes and
LTH cells was observed. Increased number of intercel-
lular communications as »gap junction« between FS
cells were also recorded.
In rat females treated perinatally with EDP, pitu-
itary TSH cells showed the signs of regression up to
peripubertal period of life. An increased number of
chromophobes, LTH and »dark« cells was also evi-
dent. In addition, intercellular spaces between the pitu-
itary cells were significantly increased.
Chronic treatment of middle-aged rat females
with nearly physiological EDP doses acted by inhibi-
ting the structure of pituitary immunoreactive TSH
cells. These changes were evident also in animals tre-
ated with EDP and calcium in combination, but to a
lesser extent than in those receiving EDP alone.
After chronic treatment of middle-aged rats with
calcium, the TSH cell degranulation and decreased
volume and number of these cells could be the signs
of their reduced synthetic capacity.
It short, pituitary glycoprotein-producing TSH
cells respond to steroid hormones applied either as a
single injection or chronically to rats of different age. It
is clear that estrogens play an essential role in the con-
trol of function and differentiation, thus modifying the
TSH cell cycle.
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DELOVANJE STEROIDNIH HORMONA NA TIREOTROPNE ]ELIJE HIPOFIZE 
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Kratak sadr`aj: Hipofiza je heterogeno tkivo sastavljeno od nekoliko vrsta }elija koje lu~e hormone, a na
ve}inu od njih deluju polni hormoni. Na{a vi{egodi{nja istra`ivanja su bila usmerena na prou~avanje odgovora
hipofiznih TSH }elija pacova razli~ite starosti na polne steroide. U tom cilju morfometrijski je ispitivana imunore-
aktivnost i sub}elijska organizacija TSH }elija hipofize pacova oba pola posle tretiranja estradiol dipropionatom
tokom neonatalnog, ili perinatalnog perioda zivota. Dobijeni rezultati nesumnjivo ukazuju na trajne inhibitorne
promene tirotropnih }elija izazvane estradiolom. Te promene se zapa`aju sve do zrelosti. Na sub}elijskom nivou
je uo~ena odlo`ena diferencijacija TSH }elija. Osim toga, posebna pa`nja je posve}ena strukturnim promenama
imunoreaktivnih TSH }elija menopauzalnih `enki pacova (14 meseci), hroni~no tretiranih estradiolom, ili kalciju-
mom, ili kombinacijom estradiola i kalcijuma. Na osnovu na{ih rezultata se mo`e zaklju~iti da pri primenjenim
eskperimentalnim uslovima i estradiol i kalcijum inhibiraju tirotropne }elije hipofize.
Klju~ne re~i: hipofiza pacova, tirotropne }elije, estradiol, kalcijum, imunohistohemija, ultrastruktura
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